| 39.83 -2.08 (-4.96%) | 07-28 13:56 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 52.38 | 1-year : | 61.18 |
| Resists | First : | 44.84 | Second : | 52.38 |
| Pivot price | 41.49  |
|||
| Supports | First : | 37.81 | Second : | 33.45 |
| MAs | MA(5) : | 41.29 |
MA(20) : | 40.62 |
| MA(100) : | 36.87 |
MA(250) : | 26.06 |
|
| MACD | MACD : | 1.1 |
Signal : | 1.3 |
| %K %D | K(14,3) : | 56.7 |
D(3) : | 60.5 |
| RSI | RSI(14): 51.3 |
|||
| 52-week | High : | 47.84 | Low : | 6.21 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ KOD ] has closed above bottom band by 13.5%. Bollinger Bands are 67.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 43.04 - 43.21 | 43.21 - 43.4 |
| Low: | 40.65 - 40.83 | 40.83 - 41.03 |
| Close: | 41.58 - 41.87 | 41.87 - 42.19 |
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.
Mon, 27 Jul 2026
Kodiak Sciences Inc (KOD) Institutional Confidence - TradingKey
Mon, 27 Jul 2026
Kodiak Sciences Inc Revenue Breakdown – BOATS:KOD - TradingView
Mon, 27 Jul 2026
Kodiak Sciences Inc (KOD) Cash Flow - TradingKey
Mon, 27 Jul 2026
KOD|Kodiak Sciences Inc|Price:42.020|Chg%:+0.610 - TradingKey
Fri, 17 Jul 2026
Kodiak Sciences Inc. (KOD) awards CFO 66,500 stock options - Stock Titan
Fri, 17 Jul 2026
Kodiak Sciences (KOD) awards CEO Perlroth 100,000 stock options - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 63 (M) |
| Shares Float | 39 (M) |
| Held by Insiders | 5.1 (%) |
| Held by Institutions | 99.6 (%) |
| Shares Short | 10,420 (K) |
| Shares Short P.Month | 10,480 (K) |
| EPS | -4.18 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.8 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -49.1 % |
| Return on Equity (ttm) | -208.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.51 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -147 (M) |
| Levered Free Cash Flow | -52 (M) |
| PE Ratio | -9.65 |
| PEG Ratio | 0 |
| Price to Book value | 22.2 |
| Price to Sales | 0 |
| Price to Cash Flow | -17.13 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|